undamentalytics Newsletter
Sign in

Abeona Therapeutics Inc. (ABEO) stock

Add to watchlist

Add holding +

NASDAQ: ABEO Nasdaq Biotechnology Next results ~November 11, 2026

D Fundamentals grade

Abeona Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$9.9

Valuation models combined (2)

Base case. Range ~$6.2–$11. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Abeona Therapeutics Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 9 selling0 purchases and 38 sales by directors and officers, last 12 monthsInsider trades
  • Funds72 adding, 44 cuttingOf 29 active managers that changed their stake, 14 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Abeona Therapeutics files

Where Abeona Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $26m, down 87.7% on a year earlier, against growth of 258.2% a quarter earlier. Free-cash-flow margin rose to -319.5% from -14268.5% a year earlier. Operating margin widened to -327.6% from -16634.2%. The diluted share count is up 36.6% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 4 of our 6 financial-health checks. Our price-to-sales vs peers value is $1.14 a share, against a share price of $4.65.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Where it stands out: long-term debt as % of assets of 0.9% ranks 14 of 78 biotechnology companies we cover. Where it lags: change in share count of 36.6% ranks 137 of 156 biotechnology companies we cover.

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 43% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 19575.2 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 87.7% over the last 12 months.
  • Growth slowing. The growth rate is 345.9 points lower than a quarter earlier.
  • Loss-making. Operating margin is -327.6%: costs exceed revenue.
  • Burning cash. Free cash flow was -319.5% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 45.4% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$0.35 against an average estimate of -$0.24: missed by 42.9%
Revenue
$11m, up 2745.0% on a year earlier
Share reaction
-19.7% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 11, 2026; average EPS estimate -$0.17

Abeona Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.3%
  • 1 week-1.4%
  • 1 month-15.5%
  • This year-19.4%
  • 1 year-11.6%
  • 5 years-81.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$25.5M
Operating margin
-327.6%
Net margin
-246.4%
EPS (TTM, diluted)
$-1.21

Growth

Share count change
+36.6%

Cash

Free cash flow (TTM)
-$81.5M
FCF margin
-319.5%
Stock pay % of revenue
45.4%

Earnings

Last results
August 13, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Abeona Therapeutics Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Abeona Therapeutics Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.08 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$11 ~$5.6–$16 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$6.2 ~$6.4–$24 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$9.9 ~$6.2–$11 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Abeona Therapeutics Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 201520162017201820202021202220232025
Share price$84.00$121.25$396.25$178.50$39.25$8.50$3.08$5.01$5.27
Market value$1.1bn$2.0bn$7.9bn$4.1bn$873m$201m$73m$321m$349m
+ Net debt (− = net cash)−$40m−$69m−$138m−$19m−$13m−$33m−$14m−$14m−$58m
Enterprise value$1.1bn$1.9bn$7.8bn$4.1bn$860m$168m$58m$307m$290m
Multiples
Price / sales n/mn/mn/mn/m87.3x66.9x51.4x91.8x59.9x
Price / earnings ————————4.9x
Price / free cash flow —————————
EV / EBITDA —————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

9 /100

Weak moat

How hard Abeona Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -40.4% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -451.2%; its worst year was -16634.2%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 9 years, at a median -477.7% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 2575.4% over five years; stock-based pay has been a median 112.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026, before the open. Analysts expect revenue of $15m and EPS of −$0.17 (range −$0.25 to −$0.05) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.95 +23% $53m +804%
Next −$0.21 +78% $116m +120%

Next year's EPS estimate has moved −172.4% in 90 days, across 4 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +39.0% on 90 days ago. In the last 30 days, 0 analysts raised Abeona Therapeutics Inc.'s forecast and 1 cut it.

Consensus EPS forecast Abeona Therapeutics Inc., last 90 days
−$1.00 −$0.50 $0.00 $0.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.68 Current fiscal year, 60 days ago: −$0.68 Current fiscal year, 30 days ago: −$0.87 Current fiscal year, 7 days ago: −$0.83 Current fiscal year, Now: −$0.95 −$0.95 Next fiscal year, 90 days ago: $0.29 Next fiscal year, 60 days ago: $0.29 Next fiscal year, 30 days ago: −$0.19 Next fiscal year, 7 days ago: −$0.04 Next fiscal year, Now: −$0.21 −$0.21

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.68$0.29
60 days ago −$0.68$0.29
30 days ago −$0.87−$0.19
7 days ago −$0.83−$0.04
Now −$0.95−$0.21

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.24 −$0.35 −42.9%
Mar 2026 −$0.39 −$0.30 +23.7%
Dec 2025 −$0.37 −$0.37 +2.1%
Sept 2025 −$0.34 −$0.11 +68.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 13, 2026

No numeric guidance in Abeona Therapeutics Inc.'s latest earnings release (filed August 13, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

7 analysts, Oct 2026
Buy7100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202677
  2. Sep 202666
  3. Aug 202666

Counts of recommendations published by analysts covering Abeona Therapeutics Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
32.3%
of tradable shares
Days to cover
11.93
at average volume
Short interest, 1 month
+9%
to October 15, 2026
Held by institutions
75%
of shares
Held by insiders
12.3%
of shares
Employees
226
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −11.6%

$4.81 on October 31, 2025 to $4.25

ThenNowEffect
Revenue (last 12 months) $1m $26m +1704.8%
P/S multiple 171.8x 9.8x −94.3%
Share count 51m 59m −13.8%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ABEO−78%−64%+63%+11%−5%−19%
Industry peers (median)−35%−56%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ABEO25%25%58%58%42%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ABEO−91%−74%−44%−64%−42%−43%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from May 17, 2018 to February 24, 2023. Getting back needed a 23733% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$4.17 – $7.46
From 52-week high
−43.0%
vs 50-day average
−18.4%
vs 200-day average
−22.5%
Volatility (1 year)
54%
Beta vs S&P 500
1.57

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±9.2%
After a week
7 up, 5 down
typical move ±8.9%
After a month
7 up, 5 down
typical move ±13.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −19.7% +0.5% −20.1% −27.2%
May 13, 2026 −1.4% +1.4% −6.3% −2.6%
March 17, 2026 −8.1% −1.1% −12.5% +8.7%
November 12, 2025 +8.6% −1.6% +0.7% +28.5%
August 14, 2025 +8.7% −0.2% +8.4% −12.7%
July 2, 2025 +5.7% +1.2% +5.0% +16.5%
May 15, 2025 +13.2% +1.1% +22.1% +10.8%
March 20, 2025 −1.0% −0.3% −3.1% −5.4%
November 14, 2024 −3.9% −1.9% −5.1% −3.4%
August 12, 2024 +12.7% +1.7% +18.3% +26.5%
May 15, 2024 +9.5% +1.0% +2.1% +8.8%
May 3, 2024 +17.4% +2.3% +3.2% +6.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Abeona Therapeutics Inc.
-$10M $0 $10M $20M $30M FY17 Q2 FY18 Q1 FY18 Q4 FY26 Q2 Revenue (TTM), FY17 Q2: $843K Revenue (TTM), FY17 Q3: $878K Revenue (TTM), FY17 Q4: $837K Revenue (TTM), FY18 Q1: $3.2M Revenue (TTM), FY18 Q2: $3.9M Revenue (TTM), FY18 Q3: $5.3M Revenue (TTM), FY18 Q4: $3M Revenue (TTM), FY19 Q1: $400K Revenue (TTM), FY19 Q2: -$419K Revenue (TTM), FY22 Q4: $1.4M Revenue (TTM), FY26 Q1: $14.5M Revenue (TTM), FY26 Q2: $25.5M $25.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY17 Q2 $843K
FY17 Q3 $878K
FY17 Q4 $837K
FY18 Q1 $3.2M
FY18 Q2 $3.9M
FY18 Q3 $5.3M
FY18 Q4 $3M
FY19 Q1 $400K
FY19 Q2 -$419K
FY22 Q4 $1.4M
FY26 Q1 $14.5M
FY26 Q2 $25.5M
Revenue growth, TTM YoY Abeona Therapeutics Inc.
-200% 0% 200% 400% 600% FY16 Q2 FY17 Q1 FY17 Q4 FY19 Q1 Revenue growth, TTM YoY, FY16 Q2: -6.0% Revenue growth, TTM YoY, FY16 Q3: -19.9% Revenue growth, TTM YoY, FY16 Q4: -14.5% Revenue growth, TTM YoY, FY17 Q1: -17.4% Revenue growth, TTM YoY, FY17 Q2: -11.2% Revenue growth, TTM YoY, FY17 Q3: 3.5% Revenue growth, TTM YoY, FY17 Q4: -5.8% Revenue growth, TTM YoY, FY18 Q1: 286.8% Revenue growth, TTM YoY, FY18 Q2: 356.8% Revenue growth, TTM YoY, FY18 Q3: 508.3% Revenue growth, TTM YoY, FY18 Q4: 258.2% Revenue growth, TTM YoY, FY19 Q1: -87.7% -87.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY16 Q2 -6.0%
FY16 Q3 -19.9%
FY16 Q4 -14.5%
FY17 Q1 -17.4%
FY17 Q2 -11.2%
FY17 Q3 3.5%
FY17 Q4 -5.8%
FY18 Q1 286.8%
FY18 Q2 356.8%
FY18 Q3 508.3%
FY18 Q4 258.2%
FY19 Q1 -87.7%
Operating margin (TTM) Abeona Therapeutics Inc.
-20000% -10000% 0% 10000% 20000% FY17 Q2 FY18 Q1 FY18 Q4 FY26 Q2 Operating margin (TTM), FY17 Q2: -2933.6% Operating margin (TTM), FY17 Q3: -2838.0% Operating margin (TTM), FY17 Q4: -3325.7% Operating margin (TTM), FY18 Q1: -1022.9% Operating margin (TTM), FY18 Q2: -969.9% Operating margin (TTM), FY18 Q3: -915.7% Operating margin (TTM), FY18 Q4: -1940.2% Operating margin (TTM), FY19 Q1: -16634.3% Operating margin (TTM), FY19 Q2: 18605.3% Operating margin (TTM), FY22 Q4: -3600.8% Operating margin (TTM), FY26 Q1: -637.9% Operating margin (TTM), FY26 Q2: -327.6% -327.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY17 Q2 -2933.6%
FY17 Q3 -2838.0%
FY17 Q4 -3325.7%
FY18 Q1 -1022.9%
FY18 Q2 -969.9%
FY18 Q3 -915.7%
FY18 Q4 -1940.2%
FY19 Q1 -16634.3%
FY19 Q2 18605.3%
FY22 Q4 -3600.8%
FY26 Q1 -637.9%
FY26 Q2 -327.6%
FCF margin (TTM) Abeona Therapeutics Inc.
-20000% -10000% 0% 10000% 20000% FY17 Q2 FY18 Q1 FY18 Q4 FY26 Q2 FCF margin (TTM), FY17 Q2: -2191.1% FCF margin (TTM), FY17 Q3: -2411.8% FCF margin (TTM), FY17 Q4: -2809.4% FCF margin (TTM), FY18 Q1: -774.6% FCF margin (TTM), FY18 Q2: -847.0% FCF margin (TTM), FY18 Q3: -682.9% FCF margin (TTM), FY18 Q4: -1612.9% FCF margin (TTM), FY19 Q1: -14268.5% FCF margin (TTM), FY19 Q2: 15249.9% FCF margin (TTM), FY22 Q4: -3084.4% FCF margin (TTM), FY26 Q1: -586.2% FCF margin (TTM), FY26 Q2: -319.5% -319.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY17 Q2 -2191.1%
FY17 Q3 -2411.8%
FY17 Q4 -2809.4%
FY18 Q1 -774.6%
FY18 Q2 -847.0%
FY18 Q3 -682.9%
FY18 Q4 -1612.9%
FY19 Q1 -14268.5%
FY19 Q2 15249.9%
FY22 Q4 -3084.4%
FY26 Q1 -586.2%
FY26 Q2 -319.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 2 4 2 1 1 1 1 3 10 3 1 4 6 26
Gross profit — — — — — — — — — — — — — 4 17
EBITDA −8 −8 −4 −4 −3 −18 −23 −27 −56 −77 −87 −48 −45 −87 −81
Operating income −8 −8 −4 −4 −3 −19 −24 −28 −58 −81 −90 −51 −47 −89 −84
Net income −8 −3 −11 4 −27 −15 −22 −27 −57 −84 −85 −40 −54 71 −63
Diluted EPS −$0.00 −$0.00 −$0.00 $0.11 −$2.12 −$0.04 −$0.05 −$1.38 −$0.10 −$0.15 −$0.14 −$1.84 −$0.84 $1.01 —
Growth (year on year)
Revenue — +282.3% +139.5% −53.6% −54.7% +12.4% −14.5% −5.8% +258.2% +233.6% −70.0% −52.9% +147.5% +66.3% —
Net income — — — — −701.9% — — — — — — — — — —
Diluted EPS — — — — <−999% — — — — — — — — — —
Margins
Gross margin — — — — — — — — — — — — — 73.7% 67.1%
EBITDA margin <−999% −415.6% −88.5% −186.1% −337.3% <−999% <−999% <−999% <−999% −768.3% <−999% <−999% <−999% <−999% −316.5%
Operating margin <−999% −428.3% −98.0% −186.3% −338.5% <−999% <−999% <−999% <−999% −814.2% <−999% <−999% <−999% <−999% −327.6%
Net margin <−999% −137.7% −239.1% 217.9% <−999% <−999% <−999% <−999% <−999% −842.3% <−999% <−999% <−999% >999% −246.4%
Free-cash-flow margin <−999% −415.9% −90.1% −0.0% −174.2% <−999% <−999% <−999% <−999% −363.6% <−999% <−999% <−999% <−999% −319.5%
Cash flow
Cash from operations −7 −8 −4 0 −2 −10 −13 −23 −39 −35 −66 −43 −37 −76 −76
Capital spending 0 0 0 0 0 0 1 1 9 1 4 0 0 8 5
Free cash flow −7 −8 −4 −0 −2 −11 −14 −24 −48 −36 −70 −44 −37 −84 −82
Stock-based pay 1 1 0 0 1 4 5 5 8 6 9 3 5 11 12
Free cash flow after stock pay −8 −9 −4 −0 −3 −15 −18 −28 −57 −42 −79 −47 −42 −95 −93
Balance sheet
Cash 7 2 0 0 12 40 69 138 19 13 33 14 14 78 56
Total debt 6 6 0 0 0 0 0 0 0 0 0 0 0 20 15
Net debt (negative = net cash) −2 3 −0 −0 −11 −40 −69 −138 −19 −13 −33 −14 −14 −58 −41
Diluted shares — 11,510m 13,927m 15m 14m 13m 16m 20m 23m 22m 24m 24m 64m 66m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 6 checks passed · June 30, 2026
What it owns · $180m
Short-term assets $165mLonger-term assets $15m
What it owes, and who funded it · $180m
Short-term liabilities $25mLonger-term liabilities $27mShareholders' equity $128m
  • Short-term assets cover short-term liabilities $165m of assets due within a year against $25m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $165m short-term assets against $27m of longer-dated liabilities.
  • More cash than debt $56m of cash against $15m of debt.
  • Debt below 40% of shareholders' equity Debt is 12% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$76m of operating cash flow against $15m of debt.
  • Operating profit covers interest at least five times over Operating income of −$84m against $3m of interest.

From Abeona Therapeutics Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+36.6%
year over year
R&D spending
99.9%
of revenue
Sales & admin spending
287.7%
of revenue
Days sales outstanding
134 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ABEO CRSP JANX STOK GLUE TNXP Median
Revenue, last 12 months $26m $25m $24m $28m $29m $29m $56m
Revenue growth, last 12 months −87.7% −34.3% >999% −86.2% −83.9% 196.0% 12.6%
Revenue growth, 3-year average 212.0% −47.1% 45.7% 46.1% — — 13.7%
Revenue growth, latest quarter >999% >999% >999% −32.5% −61.3% 577.9% 10.2%
Gross margin 67.1% — — — — 83.8% 82.9%
Operating margin −327.6% <−999% −598.1% −809.7% −633.0% −568.4% −189.4%
Operating margin, 3-year average <−999% <−999% <−999% −515.1% <−999% −881.2% −363.5%
Net margin −246.4% <−999% −427.5% −753.6% −560.8% −548.6% −169.8%
Cash from operations / revenue −299.5% <−999% −171.9% −645.2% −83.8% −525.7% −168.0%
Free-cash-flow margin −319.5% <−999% −174.7% −654.9% −111.7% −543.3% −162.4%
Free-cash-flow margin, 3-year average <−999% −793.9% <−999% −385.4% −424.9% −605.0% −310.0%
Stock pay / revenue 45.4% 276.8% 153.7% 135.7% 71.7% 27.3% 20.0%
Change in share count 36.6% 10.0% 6.2% 7.1% 11.9% — 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Gross margin Profitability 67.1% 82.4% 57 of 75
Operating margin Profitability -327.6% -189.4% 109 of 175
Net margin Profitability -246.4% -157.3% 103 of 180
Free-cash-flow margin Cash generation -319.5% -145.4% 115 of 176
Stock pay as % of revenue Cash generation 45.4% 19.2% 113 of 179
Long-term debt as % of assets Balance sheet 0.9% 20.6% 14 of 78
Change in share count Balance sheet 36.6% 7.9% 137 of 156
Days sales outstanding Balance sheet 134 days 75 days 80 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses $3.4M 58.4% —
Products $2.4M 41.6% —

From Abeona Therapeutics Inc.'s 10-K filed March 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$275M
Institutions reporting
126
Shares held vs prior quarter
▲ 12.6%
Positions opened / closed
30 / 12

Top buyers and sellers, Q2 2026: 72 institutions bought and 44 sold ; the biggest buyer was Nantahala Capital Management, LLC (+5.3M shares) and the biggest seller Montanova Capital, LLC (−2.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Nantahala Capital Management, LLC $63.5M 10.3M 23.1% ▲ 104.9%
Blackrock, Inc. $20.7M 3.4M 7.5% ▲ 4.9%
Cable Car Capital, LP $18.6M 3.0M 6.8% 0.0%
Aigh Capital Management LLC $18.5M 3.0M 6.7% ▼ 3.6%
Vanguard Capital Management LLC $13.7M 2.2M 5.0% ▲ 2.2%
Onedigital Investment Advisors LLC $10.2M 1.7M 3.7% New
Awm Investment Company, Inc. $9.2M 1.5M 3.3% ▲ 85.0%
Geode Capital Management, LLC $7.8M 1.3M 2.8% ▲ 4.2%
Kennedy Capital Management LLC $7.7M 1.2M 2.8% ▼ 1.9%
Goldman Sachs Group Inc $7.6M 1.2M 2.8% ▲ 8.3%
State Street Corp $6.4M 1.0M 2.3% ▲ 8.7%
Propel Bio Management, LLC $6.1M 983K 2.2% ▼ 26.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Abeona Therapeutics Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $3.6M 38 trades by 9 insiders · 19% under pre-set plans
Net ▼ $3.6M net selling
Insider Date Trade Shares Price Value
Vasanthavada Madhav Chief Commercial Officer September 29, 2026 Sell 4,902 $5.16 $25,294
O'Malley Brendan M. SVP, Chief Legal Officer September 29, 2026 Sell 6,727 $5.16 $34,711
Vazzano Joseph Walter Chief Financial Officer September 29, 2026 Sell 9,191 $5.16 $47,426
Seshadri Vishwas Chief Executive Officer September 29, 2026 Sell 19,608 $5.16 $101,177
Alvino Mark Director September 1, 2026 Sell 15,000 $5.86 $87,900
Vazzano Joseph Walter Chief Financial Officer July 21, 2026 Sell 1,478 $6.53 $9,651
Vasanthavada Madhav Chief Commercial Officer July 9, 2026 Sell 12,606 $6.96 $87,738
O'Malley Brendan M. SVP, Chief Legal Officer July 9, 2026 Sell 12,050 $6.96 $83,868
Seshadri Vishwas Chief Executive Officer July 9, 2026 Sell 67,971 $6.96 $473,078
Vazzano Joseph Walter Chief Financial Officer July 9, 2026 Sell 24,880 $6.96 $173,165
Alland Leila Director June 30, 2026 Sell 11,000 $5.92 $65,120
Silverstein Christine Berni Director June 15, 2026 Sell 18,160 $5.71 $103,694

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 13, 2026
  • March 17, 2026
  • November 12, 2025
  • August 14, 2025
  • July 2, 2025

Recent SEC filings

Data status

When each part of this page on Abeona Therapeutics Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Abeona Therapeutics Inc. in brief

What does Abeona Therapeutics Inc. do?
Abeona Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Abeona Therapeutics Inc.'s stock ticker?
Abeona Therapeutics Inc. trades under the ticker ABEO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Abeona Therapeutics Inc.'s free cash flow?
Abeona Therapeutics Inc.'s free-cash-flow margin is -319.5% of revenue over the trailing twelve months, ranking 115 of the 176 biotechnology companies we cover.
Who are Abeona Therapeutics Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Nantahala Capital Management, LLC, Blackrock, Inc. and Cable Car Capital, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Abeona Therapeutics Inc.'s market cap?
On December 31, 2025, Abeona Therapeutics Inc.'s market capitalisation was about $349M, with a price-to-earnings ratio of 4.9 and net debt of -$58.4M. Market figures come from third-party market data and may be delayed.
How much debt does Abeona Therapeutics Inc. have?
Abeona Therapeutics Inc.'s debt-to-equity ratio is 11.7%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Abeona Therapeutics Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Abeona Therapeutics Inc. are Crispr Therapeutics AG, Janux Therapeutics, Inc., Stoke Therapeutics, Inc., Monte Rosa Therapeutics, Inc. and Tonix Pharmaceuticals Holding Corp. The side-by-side comparison below sets their revenue, margins and growth against Abeona Therapeutics Inc.'s.
Are insiders buying or selling Abeona Therapeutics Inc. stock?
Over the last 12 months, Abeona Therapeutics Inc.'s directors and officers reported 0 open-market purchases and 38 sales on Form 4. The insider trading page charts every trade.
When is Abeona Therapeutics Inc.'s next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Abeona Therapeutics Inc. announces its own schedule.